IGFBP4 and COVID-19: 9 of the 11 differentially expressed factors were significantly increased in COVID-19 patients compared with healthy controls: TRAIL R1, IGFBP-1, IGFBP-4, VCAM-1, sFRP-3, FABP2, Transferrin, GDF15, and CD200 (P < 0.01).